Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
Details : Focinvez (fosaprepitant) is the first ready-to-use, single-dose injection to prevent acute and delayed nausea & vomiting from emetogenic cancer chemotherapy in adults and children 6 months and older.
Brand Name : Focinvez
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces New Product Launches and Participation in DCAT Week 2024
Details : Emend-Generic (fosaprepitant) is an NK1 receptor antagonist for preventing nausea and vomiting in adults and pediatric patients aged 6 months and older during chemotherapy.
Brand Name : Emend-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2024
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Techdow USA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.
Brand Name : Emend-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 22, 2023
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Techdow USA
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Launches Fosaprepitant for Injection
Details : Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend® for Injection, 150 mg Single-Dose Vial, of Merck indicated for adults in combination with other antiemetic agents.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?